FLT3: A narrative review
The adoption of next-generation sequencing (NGS) has unraveled myriad genomic alterations across all myeloid malignancies, changing not only the prognostic paradigm but also the therapeutic paradigm. Many alterations have been incorporated in the classification and categorization of these neoplasia...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Cancer Research, Statistics, and Treatment |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/crst.crst_192_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850138925038829568 |
|---|---|
| author | Nikhil M Kumar Shrinidhi Nathany Anusha Swaminathan Chitresh Yadav Akriti Kothari Paritosh Garg Neha Panda-Rastogi Vikas Dua Arun Danewa Rahul Bhargava |
| author_facet | Nikhil M Kumar Shrinidhi Nathany Anusha Swaminathan Chitresh Yadav Akriti Kothari Paritosh Garg Neha Panda-Rastogi Vikas Dua Arun Danewa Rahul Bhargava |
| author_sort | Nikhil M Kumar |
| collection | DOAJ |
| description | The adoption of next-generation sequencing (NGS) has unraveled myriad genomic alterations across all myeloid malignancies, changing not only the prognostic paradigm but also the therapeutic paradigm. Many alterations have been incorporated in the classification and categorization of these neoplasia by the World Health Organization (WHO) in its 5th edition of the classification for hematolymphoid neoplasms, as well as international consensus classifications. One among them is the Feline McDonough sarcoma tyrosine kinase 3 (FLT3). Since time immemorial, many studies have been conducted to understand the clinico-pathologic features, including responses to small molecules developed for the same. A lot of emphasis has been placed on the allele ratio and mutation burden, the concept of which has now been abolished owing to evidence-based medicine validating no differences in outcomes between high- and low-allele ratio diseases. The advent of FLT3 inhibitors has changed the therapeutic landscape of FLT3-mutated cases and is categorized as intermediate risk. Despite remarkable development and understanding of the disease, a lot remains to be understood. This is a narrative review elucidating the biology, alterations, clinico-pathologic features, detection methods, therapeutic strategies, prognosis, and newer developments in the context of FLT3. We searched PubMed, Embase, and Scopus databases using the keywords FLT3, tyrosine kinase inhibitors (TKI), acute myeloid leukemia (AML), and internal tandem duplications (ITD). No formal inclusion or exclusion criteria were set, as this is a narrative review. A total of 59 articles were reviewed to construct this article. |
| format | Article |
| id | doaj-art-fa69e294b65a470bb8d78b6b45c7be59 |
| institution | OA Journals |
| issn | 2590-3233 2590-3225 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Cancer Research, Statistics, and Treatment |
| spelling | doaj-art-fa69e294b65a470bb8d78b6b45c7be592025-08-20T02:30:28ZengWolters Kluwer Medknow PublicationsCancer Research, Statistics, and Treatment2590-32332590-32252025-01-0181667410.4103/crst.crst_192_24FLT3: A narrative reviewNikhil M KumarShrinidhi NathanyAnusha SwaminathanChitresh YadavAkriti KothariParitosh GargNeha Panda-RastogiVikas DuaArun DanewaRahul BhargavaThe adoption of next-generation sequencing (NGS) has unraveled myriad genomic alterations across all myeloid malignancies, changing not only the prognostic paradigm but also the therapeutic paradigm. Many alterations have been incorporated in the classification and categorization of these neoplasia by the World Health Organization (WHO) in its 5th edition of the classification for hematolymphoid neoplasms, as well as international consensus classifications. One among them is the Feline McDonough sarcoma tyrosine kinase 3 (FLT3). Since time immemorial, many studies have been conducted to understand the clinico-pathologic features, including responses to small molecules developed for the same. A lot of emphasis has been placed on the allele ratio and mutation burden, the concept of which has now been abolished owing to evidence-based medicine validating no differences in outcomes between high- and low-allele ratio diseases. The advent of FLT3 inhibitors has changed the therapeutic landscape of FLT3-mutated cases and is categorized as intermediate risk. Despite remarkable development and understanding of the disease, a lot remains to be understood. This is a narrative review elucidating the biology, alterations, clinico-pathologic features, detection methods, therapeutic strategies, prognosis, and newer developments in the context of FLT3. We searched PubMed, Embase, and Scopus databases using the keywords FLT3, tyrosine kinase inhibitors (TKI), acute myeloid leukemia (AML), and internal tandem duplications (ITD). No formal inclusion or exclusion criteria were set, as this is a narrative review. A total of 59 articles were reviewed to construct this article.https://journals.lww.com/10.4103/crst.crst_192_24flt3gilteritinibitdmidostaurinsorafenib |
| spellingShingle | Nikhil M Kumar Shrinidhi Nathany Anusha Swaminathan Chitresh Yadav Akriti Kothari Paritosh Garg Neha Panda-Rastogi Vikas Dua Arun Danewa Rahul Bhargava FLT3: A narrative review Cancer Research, Statistics, and Treatment flt3 gilteritinib itd midostaurin sorafenib |
| title | FLT3: A narrative review |
| title_full | FLT3: A narrative review |
| title_fullStr | FLT3: A narrative review |
| title_full_unstemmed | FLT3: A narrative review |
| title_short | FLT3: A narrative review |
| title_sort | flt3 a narrative review |
| topic | flt3 gilteritinib itd midostaurin sorafenib |
| url | https://journals.lww.com/10.4103/crst.crst_192_24 |
| work_keys_str_mv | AT nikhilmkumar flt3anarrativereview AT shrinidhinathany flt3anarrativereview AT anushaswaminathan flt3anarrativereview AT chitreshyadav flt3anarrativereview AT akritikothari flt3anarrativereview AT paritoshgarg flt3anarrativereview AT nehapandarastogi flt3anarrativereview AT vikasdua flt3anarrativereview AT arundanewa flt3anarrativereview AT rahulbhargava flt3anarrativereview |